Baird served as co-manager on this offering
AboutEiger Biopharmaceuticals Inc. (“Eiger” or the “Company”) (NASDAQ:EIGR) recently completed an underwritten public offering of 5,175,000 shares of its common stock at a price to the public of $11.00 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 675,000 shares of common stock. Net proceeds to Eiger from the offering were approximately $53.2 million after deducting underwriting discounts and the estimated expenses of the offering. Eiger intends to use the net proceeds from this offering to fund activities in connection with the HDV clinical development programs, including advancing peginterferon lambda into a potentially registrational program, supporting pipeline activities, and working capital and general corporate purposes.
Eiger is a late stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases. The Company innovates by developing well-characterized drugs in newly identified or novel targets in rare diseases. Eiger's mission is to systematically reduce the time and cost of the drug development process to more rapidly deliver important medicines to patients. Eiger is headquartered in Palo Alto, California.
CONTACT US TO LEARN MORE
- April 2019
- Eiger Biopharmaceuticals Inc.
- Target Location
- North America